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Abstract
Background: In France, 1/3 HIV-infected patients is diagnosed at an advanced stage of the disease. We describe
missed opportunities for earlier HIV testing in newly-HIV-diagnosed patients.
Methods: Cross sectional study. Adults living in France for ≥1 year, diagnosed with HIV-infection ≤6 months earlier,
were included from 06/2009 to 10/2010. We collected information on patient characteristics at diagnosis, history of
HIV testing, contacts with healthcare settings, and occurrence of HIV-related events 3 years prior to HIV diagnosis.
During these 3 years, we assessed whether or not HIV testing had been proposed by the healthcare provider upon
first contact in patients notifying that they were MSM or had HIV-related conditions.
Results: 1,008 newly HIV-diagnosed patients (mean age: 39 years; male: 79%; MSM: 53%; diagnosed with an AIDS-
defining event: 16%). During the 3-year period prior to HIV diagnosis, 99% of participants had frequented a
healthcare setting and 89% had seen a general practitioner at least once a year. During a contact with a healthcare
setting, 91/191 MSM (48%) with no HIV-related conditions, said being MSM; 50 of these (55%) did not have any HIV
test proposal. Only 21% (41/191) of overall MSM who visited a healthcare provider received a test proposal.
Likewise, 299/364 patients (82%) who sought care for s had a missed opportunity for HIV testing.
Conclusions: Under current screening policies, missed opportunities for HIV testing remain unacceptably high. This
argues in favor of improving risk assessment, and HIV-related conditions recognition in all healthcare facilities.
Keywords: HIV/AIDS, HIV testing, Late diagnosis, Risk assessment, Access to care
Background
In the past decade in developed countries, highly active
antiretroviral therapies have dramatically decreased HIV
infection morbidity and mortality [1-3]. When HIV care is
initiated early, patient’s life expectancy becomes closer to
that of the general population [4,5]. More recently, com-
pelling evidence has demonstrated benefits of early treat-
ment of HIV-infected patients for the global population by
reducing HIV transmissions [6,7]. Consequently in some
countries like US or France, treatment guidelines have
moved toward initiating earlier HIV therapy, i.e. at CD4
cell counts <500/mm3 [8-10]. However, most patients are
diagnosed long after the optimal moment of treatment ini-
tiation. Recent studies estimated that approximately 30%
of people living with HIV in Europe are unaware of their
infection [11]. Other studies, mostly from western Europe,
estimated that 24-39% of HIV-infected patients presented
for care at an advance stage of the disease (with AIDS
and/or CD4 cell count <200/mm3) [12-19]. Late diagnosis
compromises benefits of antiretroviral therapies.
In most European countries, risk-factor-based HIV
testing strategy alone shows limits to detect HIV-
infected people because 1) people do not consider them-
selves at risk and 2) healthcare providers fail in risk
assessment [20-24]. In line with the US CDC recom-
mendations [25,26], in 2008 the UK guidelines stated
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that HIV screening should be considered in general
practice and for all general medical admissions in re-
gions where HIV prevalence exceeds two per 1,000 [27].
In 2009, new French guidelines recommended one-time
routine voluntary HIV screening to be implemented
population-wide in France [28,29]. However, these rec-
ommendations are not applied because of feasibility and
budget impact issues [30-32].
Few studies have evaluated patient consultations during
the possibly-HIV-infected period [22,33-36], and the bulk
of them were carried out in the US or the UK. To assess
the situation in France, the objectives of the present study
conducted in newly diagnosed HIV-infected patients were
to describe: 1) in all patients, frequenting of healthcare set-
tings prior to HIV diagnosis during the period in which
they were likely to be HIV-infected; and 2) in at-risk popu-
lations (MSM) and patients with possibly HIV-related
conditions, opportunities for testing proposal and conse-
quently earlier HIV diagnosis.
Methods
Study design, setting and population
A cross-sectional study was conducted between June
2009 and October 2010 in 69 ANRS centers providing
care to patients with HIV throughout France (metropol-
itan France and French overseas departments). The
study was proposed to all the ANRS centers (around
160) on a voluntary basis; 64 centers accepted to partici-
pate and enrolled effectively patients. The two mains
reasons for not participating were lack of manpower and
too few new HIV-infected patients per year. However,
centers from smaller hospitals were recruited to ensure
geographic coverage of French territories.
Patients were eligible for this study if they were over
18-years-old, had an initial HIV-positive test (diagnosis)
in France, and sought care in a participating center
within the 6-month period following HIV diagnosis. Pa-
tients diagnosed in a foreign country or who had been
living for ≤1 year in France were excluded, since oppor-
tunities for testing were not in France. Eligible patients
were consecutively enrolled during the study period.
The study received approval from two French data
protection authorities (CCTIRS and CNIL) and did not
require formal ethical approval according to French reg-
ulations. All patients received information and gave writ-
ten consent before their inclusion in the study.
Definition
We defined situations that would lead care providers to
suggest HIV testing, i.e. to persons belonging to a high-
risk group for HIV acquisition and who presented with
HIV-related clinical conditions. Risk groups for acquir-
ing HIV infection were (by descending risk) [37]:
injected drug users (IDU), men who have sex with men
(MSM), heterosexuals with at-risk behavior (≥2 sexual
partners and/or unprotected sex with casual partners
within the past three years) and immigrants from an
HIV endemic country of Sub-Saharan Africa (born and
living there until moving to France). For patients belong-
ing to several risk groups, the group with the highest
risk was retained.
Possibly HIV-related conditions included symptoms
more frequent during chronic stage of HIV infection
and diseases associated with a high HIV prevalence
(>1%) [35,37-40]:
– General symptoms: fever unexplained and/or lasting
≥1 month; diarrhea recurrent and/or lasting for ≥1
month; weight loss ≥10%;
– Cutaneous/mucous symptoms: seborrheic
dermatitis; oral herpes; oral hairy leukoplakia; oral
candidiasis; varicella zoster; onychomycosis;
unexplained prurigo. This class also included
generalized lymphadenopathy;
– Bacterial infections: community-acquired
pneumonia, pulmonary tuberculosis, recurrent
bacterial infections;
– Diseases associated with high prevalence of HIV
infection: viral hepatitis A, B or C, and sexually
transmitted infections (STIs): syphilis; gonorrhea;
chlamydia; genital herpes; genital condyloma /
human papilloma virus; lymphogranuloma venereum
proctitis infection; genital mycoplasma;
trichomoniasis.
AIDS-defining opportunistic infections, except for pul-
monary tuberculosis, were not considered in this ana-
lysis. Indeed, we hypothesized that HIV testing would be
performed during the diagnostic process surrounding
these events.
Main outcomes
Patients were asked about their encounters with
healthcare settings and HIV testing history during the
three years prior to HIV diagnosis. For patients belong-
ing to a high-risk group, we determined whether, in the
3-year period prior to HIV diagnosis, they had seen a
healthcare provider and, if so, mentioned that they
belonged to a high-risk group. For patients presenting
with possibly HIV-related conditions, we determined
whether they had seen a healthcare provider. Among pa-
tients who had seen a healthcare provider from both
groups, we determined whether an HIV test had been
proposed during the first visit. Medical encounters be-
tween patients from high risk groups or with a possibly
HIV-related condition and any healthcare provider,
which did not lead to a test proposal, were defined as
missed opportunities for HIV testing.
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When evaluating patient medical history during the
past three years, we considered that a patient to whom a
test had not been proposed was probably HIV-infected
at the time of this contact if: (i) he/she did not report an
HIV-negative test after this contact; or (ii) he/she was
not diagnosed at an acute HIV infection stage (defined
as an incomplete western blot, detectable Agp24, or de-
tectable plasma viral load, with a negative or weakly
ELISA, or an interval <3 months between a negative and
positive ELISA test [41]).
Data collection
The face-to-face interview used a standardized question-
naire that anonymously collected information on patient
socio-demographic characteristics, risk factors for HIV
acquisition, date of the first HIV-positive test, clinical
and immunological characteristics at HIV diagnosis, his-
tory of HIV testing, contacts with healthcare settings,
and clinical events. Possibly HIV-related conditions, oc-
curring during the three years prior to HIV diagnosis,
were to be detailed. Patients belonging to high-risk
groups and/or presenting with possibly HIV-related con-
ditions and who had seen a healthcare provider were
questioned regarding which healthcare facility they had
visited and whether or not an HIV test had been
proposed.
Sample size estimate
Age has been found to be associated with missed oppor-
tunities for HIV testing in US studies [22,35]. Based on
results from studies that have explored delayed HIV test-
ing and hypothesizing that patients with delayed HIV
testing are also those with missed opportunities, we ex-
pect that 9% of patients with missed opportunities for
HIV testing are >50 years of age [14]. For an OR of 2 to
be significant when comparing HIV testing missed op-
portunities in people aged >50 years versus those aged
≤50, assuming an alpha-risk of 5%, a 1-beta risk of 80%,
and a bilateral test, 196 people aged >50 and 784 people
aged ≤50 had to be enrolled in the study.
Statistical analysis
Descriptive statistical methods were used to describe the
study population and opportunities for HIV testing.
Continuous data were compared using the Wilcoxon
rank test and categorical data using the Fisher exact test.
P-values ≤0.05 (two-tailed) were considered significant.
To differentiate between missed opportunities for test-
ing in patients “belonging to a high risk group” and
those “presenting with possibly HIV-related conditions”,
we considered only patients without a past history of
possible HIV-related conditions when we evaluated op-
portunities for HIV testing in patients belonging to a
risk group.
HIV-related conditions occurring within the 3-month
period prior to HIV diagnosis were considered to be dir-
ectly related to diagnosis. Testing opportunities were
therefore evaluated only in patients who had presented
HIV-related conditions between 3 years and 3 months
prior to HIV diagnosis. When multiple HIV-related con-
ditions had occurred during that period, we included in
the analysis only the earliest HIV-related conditions.
Center effect impact on missed opportunities rate for
HIV testing was studied by regrouping centers base HIV
low of high new diagnosis rate (cut-off: 80 HIV positive
tests per million inhabitants [19]). Chi2 test was used for
the comparisons.
Statistical analyses were performed using SAS 9.2 soft-
ware (SAS Institute Inc., Cary, NC, USA).
Results
During the study period, 2,009 newly diagnosed HIV-
infected patients sought care in the 69 participating cen-
ters throughout France. Overall, 659 (33%) were ex-
cluded because they did not fulfill inclusion criteria: 288
had been living in France for <1 year, 95 had had the ini-
tial HIV-positive test performed abroad, 148 sought care
≥6 months after HIV diagnosis, 18 were aged ≤18 years,
and 110 were excluded for other reasons (mainly be-
cause they did not speak French). The study was not
proposed to 227 patients mainly because of time pres-
sure and lack of availability of care providers, and 115
more patients refused to participate in the study. Finally,
1,008 patients (50%) were enrolled. The overall 2,009 pa-
tients who sought care in study centers were not differ-
ent from newly diagnosed HIV-infected patients in
France during the same period [42] in terms of sex, age,
clinical or immunological characteristics at HIV diagno-
sis (Table 1). However, the 1,008 patients enrolled in the
study were more frequently men, older, born in France,
diagnosed during acute HIV infection when compared
with patients not enrolled.
Socio-demographic characteristics at HIV diagnosis
(Table 2)
Patient’s median age was 39.5 years; 793 (79%) were
males. More than 80% belonged to a high risk group, 12
(1%) were IDU, 530 (53%) were MSM, 155 (15%) were
heterosexuals with risky behavior and 124 (12%) were
migrants from Sub-Saharan Africa (Table 2). Most had
low educational attainment (high school level or less =
61%). Patients were well insured at the time of HIV diag-
nosis: 772 (77%) had complete health insurance (i.e.
basis, plus supplementary health insurance or universal
medical coverage); only 54 (5%) were not insured prior
to HIV diagnosis.
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History of HIV testing
Except for the test leading to HIV diagnosis, 407 (41%)
participants had been tested within the last three years,
273 (27%) had been previously tested but more than
three years ago and the remaining 325 (32%) had never
been tested for HIV. Among MSM, 94 (18%) had never
been tested. In contrast, 45% of sub-Saharan African mi-
grants, 44% of heterosexuals with risky behavior, and
57% of patients who stated not belonging to a risk group
had never been tested (p < 0.0001 versus MSM). Among
migrants from sub-Saharan Africa, 43 (35%) had a his-
tory of HIV testing in France.
Clinical and immunological characteristics at HIV
diagnosis
HIV was diagnosed during acute infection in 153 (15%)
patients (Table 1). At diagnosis, 162 (16%) had had an
AIDS-defining event and 308 (31%) a CD4 cell count
<200 cells/mm3. The main circumstances leading to HIV
diagnosis were the presence of clinical symptoms for
564 patients (56%), voluntary testing for 264 patients
(26%) and health check-up for 176 patients (17%) - in-
cluding systematic prenatal testing (4%).
Contact with the healthcare system during the three
years prior to HIV diagnosis
Among the 1,008 patients enrolled in the study, 994
(99%) had had ≥1 medical encounter during the 3 years
prior to HIV diagnosis: 922 (93%) with a general practi-
tioner and 329 (33%) with an emergency department
(Table 3). Up to 90% of patients visited a general practi-
tioner at least once a year.
Opportunities for HIV testing in patients belonging to
high risk groups (MSM)
As asymptomatic patients from high-risk groups other
than MSM were not in sufficient numbers, description
of opportunities for HIV testing in people belonging to
high-risk groups were restricted to MSM. Among the
530 MSM enrolled in the study (Figure 1a), 191 reported
no possibly-HIV-related conditions and ≥1 contact with
a healthcare setting in the past 3-year period. During
this contact, 91 (48%) stated to the healthcare provider
that they belonged to a high-risk group. Upon first con-
tact, an HIV test was proposed by the healthcare pro-
vider to 41 of these 91 MSM (45%). Consequently, 150
MSM of overall 191 asymptomatic MSM (79%) were not
tested and had a missed opportunity for HIV testing.
Upon HIV diagnosis, median CD4 count tend to be
lower in patients who did not state the healthcare pro-
vider that they were MSM compared to those who did
so (400 vs. 468 cells/mm3, p = 0.08). Among those who
stated, median CD4 cell count at diagnosis was not dif-
ferent in MSM whether the test was proposed or not.
Opportunities for HIV testing in patients with possibly
HIV-related conditions
Overall, 364 out of 588 patients who reported a possibly
HIV-related conditions during the 3-year to 3-month
period prior to HIV diagnosis sought care (Figure 1b).
More than half (193/364) sought care for this condition
first with a general practitioner, 24% with a medical spe-
cialist, 4% with an inpatient service, and 3% with an
emergency department.
An HIV test was proposed by the healthcare provider
upon first contact to 65 (18%) of these patients. Thus,
299 patients (82%) had a missed opportunity for HIV
testing, and 233 (78%) of them were probably infected at
the time of this contact (no subsequent HIV test and
not diagnosed at an acute HIV infection stage). At HIV
diagnosis, median CD4 count was 274 cells/mm3 (IQR,
111–507) in patients with a missed opportunity for HIV
testing vs. 432 cells/mm3 (IQR, 308–621) in those to
whom testing was proposed (p < 0.0001).
Results were similar when detailed by HIV-related
condition (Table 4). The proportion of HIV testing pro-
posal by the healthcare provider upon the first visit by
patients who sought care for a possibly HIV-related
Table 1 Characteristics of patients diagnosed with HIV during the study period
Patients included
N = 1,008
Patients not included
N = 1,001
p Total
N = 2,009
2009 French surveillance
data
Sex, number of men (%) 793 (79%) 599 (60%) <0.0001 1392 (69%) 67%
Born outside of France, n (%) 267 (27%) 418 (52%) <0.0001 785 (39%) 47%
HIV stage at diagnosis, n (%)
CD4 <200/mm3 308 (31%) 254 (25%) 0.72 562 (28%) 28%
AIDS 162 (16%) 133 (13%) 0.18 295 (15%) 14%
Acute infection 153 (15%) 87 (9%) 0.0002 240 (12%) 10%
Age at HIV diagnosis, mean (SD) 39.5 (11.6) 35.7 (11.7) <0.0001 37.6 (11.8) 38.2
Characteristics at HIV diagnosis of patients included or not included in the study from June 2009 to October 2010, versus characteristics of newly HIV-diagnosed
patients in 2009 in France (data from French HIV/AIDS surveillance system [42]).
SD: standard deviation.
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Table 2 Socio-demographic characteristics and HIV testing history of newly HIV-diagnosed patients at diagnosis
(n = 1,008)
na %
Sex, men 793 79
Age, years
18-29 225 22%
30-49 595 59%
≥ 50 188 19%
Risk factor for HIVb
Intravenous drug user 12 1%
Man who has sex with men 530 53%
Sub-Saharan African immigrant 124 12%
Heterosexual with high risk behavior 155 15%
No identified risk 187 19%
Educational attainment
No certificate 69 7%
High school level (included professional certificate) 542 54%
University level, ≤2 years post high school certificate 146 14%
University level, >2 years post high school certificate 236 23%
Occupational class
Farmers, manual workers 85 8%
Shopkeepers, craftsmen, and office, sales and services employees 479 48%
Professionals, managers and intermediate white-collar workers 242 24%
Unemployed, including retirees and studentsc 191 19%
Marital status
Single 520 52%
Living in couple 358 36%
Divorced or widowed 125 12%
Children, ≥1 401 40%
Health insurance at time of diagnosisd
Basic health insurance 828 83%
Universal medical coveraged 89 9%
Medical aid from statee 32 3%
Uninsured or under affiliation 54 5%
Supplementary health insurance 725 72%
History of HIV testing
Never tested 325 32%
HIV tested >3 years 273 27%
HIV tested ≤3 years 407 41%
aDepending on variables, missing data were from 0 to 1.5% and are accounted for in the percentages.
bIndividual class by descending risk: IDU, MSM, Sub-Saharan African migrants, heterosexual with sexual risk, not belonging to a risk group.
c32 (3%) retirees; 38 (4%) students.
dIn France, a universal health care insurance system covers around ¾ of healthcare expenditures. Workers and retirees who contribute to social insurance are
covered by the system. Supplemental coverage may be bought by patients from private insurers. The universal medical coverage (complete or supplementary)
extends health insurance for all poor legal residents.
eComplete health insurance for refugees.
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condition was low, ranging from 2% for patients with re-
current bacterial infections to 23% for patients with a
fever lasting ≥1 month. An HIV test was proposed to
half of the patients seeking care for STIs.
The proportions of missed opportunities for HIV test-
ing in any circumstances were not different between
clinical centers when classified following epidemiological
characteristics of their belonging regions (data not
shown).
Discussion
This study, which included more than one thousand
newly HIV-diagnosed patients in France, demonstrated
that 99% of the patients had had at least one medical en-
counter during the 3-year period prior to HIV diagnosis,
and 89% had seen a general practitioner at least once a
year during that period. Moreover, results revealed the
high proportion of missed opportunities for HIV testing
among MSM and those seeking care for possibly HIV-
related conditions. Seventy nine percent of overall MSM
who visited a healthcare provider did not receive an HIV
test proposal. Likewise, HIV testing was not proposed by
the healthcare provider to 82% of patients who sought
care for possible HIV-related conditions upon first
contact.
This study had some strengths and limitations. We en-
rolled 1,008 newly-HIV-diagnosed patients, who acco-
unted for 16% of new HIV diagnoses in France during
the same period [19]. Enrolled patients were not repre-
sentative of overall newly HIV diagnosed patients be-
cause of eligibility criteria. In order to study missed
opportunities possibly occurring in France, patients diag-
nosed overseas or living in France for <1 year were ex-
cluded; hence, migrants were underrepresented (27% vs.
47% recorded in 2009 French surveillance data [42]) and
MSM were overrepresented (53% vs. 38% recorded in
2009 French surveillance data [42]). Migrants were more
likely women, young and being diagnosed for HIV at
chronic or advanced stage of HIV infection [42] that ex-
plains difference in enrolled and non-enrolled patients.
However, characteristics of overall patients were close to
those of French surveillance data, and our study sample
may be representative of patients who acquired HIV in
France.
We evaluated the patient course through the healthcare
system in the years prior to HIV diagnosis. That may be
subject to recall bias, leading to an underestimation of the
number of missed opportunities. To limit this bias, pa-
tients diagnosed >6 months previously were excluded, and
the period during which retrospective data were collected
was restricted to three years. Another limitation may be
the misperception of being tested. On one hand, some
patients may be tested without knowing the test was
performed, without the consent process, leading to over-
estimate missed opportunities proportion. On another
hand, some patients may think having been tested for HIV
because a blood analysis was performed during an in-
patient stay for example, which may this time, underesti-
mate missed opportunities proportion.
In MSM or patients presenting with possibly HIV-
related conditions, we determined whether an HIV test
was proposed upon first contact with the healthcare set-
ting. This may underestimate the HIV test proposal rate,
since HIV infection may be brought up at the second or
a later visit. First, the effect of this bias was reduced by
accounting only for visits that had occurred >3 months
before HIV diagnosis, ensuring these events did not lead
to HIV diagnosis. Next, a high proportion of patients
with missed opportunities for HIV testing did not
undergo any other HIV test prior to the test that diag-
nosed the HIV infection.
Only a few asymptomatic people belonging to a high-
risk group other than MSM, i.e. sub-Saharan African mi-
grants or heterosexuals with risky sexual behavior, were
enrolled in the study and therefore we could not deter-
mine missed opportunities for them.
Our results are cause for concern and are in agree-
ment with those reported in the medical literature that
overall estimated high proportions of missed opportun-
ities for HIV testing. However, a comparison of our re-
sults with other studies on the topic is difficult. Our
study is unique in that it investigated the overall patient
trajectory though the healthcare system; thus, it evalu-
ated HIV testing strategies based on risk factors and
symptoms such as applied currently. Most other studies
Table 3 Patient’s contacts with the healthcare system
during the three years prior to HIV diagnosis
n %
Contact with a healthcare setting 994
General practitioner 922 93%
Medical specialist 649 65%
Hospital 324 33%
Emergency department 329 33%
Other medical department or practitioner 377 38%
Annual frequency of encounters with general practitioner
Never, or did not know 106 11%
Once a year 286 29%
Two to six times a year 511 51%
At least once a month 91 9%
Time between last medical encounter and HIV diagnosis
≤1 year 826 84%
>1 year 93 9%
Did not know 75 7%
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[22,33-35,43] were conducted in the US at single large
urban medical centers with designs based on retrospect-
ive medical chart reviews; opportunities for testing that
might occur in other facilities could not be collected
[22,34,35], thereby underestimating missed opportunities
for HIV testing in those studies compared to ours. The
population enrolled in other studies was also different
from ours in that they focused on specific subgroups; for
example, late presenters [33], patients attending STI
clinics [36] or immigrants [44]. Moreover, they used dif-
ferent definitions of a missed opportunity. Some authors
defined a missed opportunity for testing in newly HIV-
diagnosed patients as any medical appointment in the
years prior to HIV diagnosis [44]. Others added to this
definition the notification of HIV-related risks and/or
clinical events (with events varying from one study to
another [22,34,36]). Very few authors coupled the pres-
ence of HIV-related risks and/or clinical events with the
a) Opportunity for HIV test proposal based on high-risk group of acquiring HIV
Fate of MSM upon first contact with a healthcare setting within the 3-year to 3-month period prior to diagnosis of HIV 
MSM who reported no possible HIV-related symptom during the period
41 (45%) to whom an
HIV test was proposed
upon first contact
CD4b=449
91 (48%) stated 
they were MSM 28 (56%) not infected at
CD4b=468 time of first contacta
50 (55%) to whom an CD4b=542
HIV test was not proposed
191 MSM upon first contact
CD4b=486
Missed opportunity 22 (44%) in possibly 
infected period
100 (52%) did not state CD4b=360
they were MSM
CD4b=400
b) Opportunity for HIV test proposal based on possible HIV-related condition
Fate of patients seeking care for possible HIV-related symptoms upon first contact with a healthcare setting within the
3-year to 3-month period prior to HIV diagnosis  
65 (18%) to whom an
HIV test was proposed
upon first contact
CD4b=432
364 (62%)  
sought care 66 (22%) not infected at
CD4b=321 time of first contacta
299 (82%) to whom an CD4b=549
HIV test was not proposed
588 patients upon first contact
with a condition CD4b=274
Missed opportunity 233 (78%) in possibly 
infected period
224 (38%) CD4b=210
did not seek care
CD4b=312
Figure 1 Opportunity for HIV testing proposal. Opportunity for HIV testing proposal based on (a) group at high risk of acquiring HIV
(asymptomatic MSM) and (b) any possibly HIV-related condition, among the 994 patients who had contact with the healthcare system in the
three years prior to HIV diagnosis. When considering opportunities for HIV testing based on a high-risk group, only patients with no HIV-related
conditions in the three years prior to HIV diagnosis were included in the analysis. When considering opportunities for HIV testing based on a HIV-
related condition, the first (oldest) symptom reported in the 3-year to 3-month period prior to HIV diagnosis was included in the analysis.aPatients
were a posteriori known not infected for HIV at the first contact when they reported a negative HIV test after this contact or they diagnosed for
HIV at acute stage. Others were considered to be possibly infected. bMedian CD4 count at diagnosis, cells/μL.
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absence of a test proposal by the care provider, which is
the definition that we used [35]. As a result, the propor-
tions of missed opportunities for HIV testing in the
medical literature range from 20 to 80%.
Our study illustrates the failure to identify persons at
high risk of being HIV-positive. In the past three years,
>80% of the 191 asymptomatic MSM had seen a
healthcare provider. However, only 48% of them in-
formed the provider, either spontaneously or upon
questioning, that they belonged to a risk group. Indeed,
patients may be wary of the healthcare setting, fearing
moral judgment of their behavior, leading to unwilling-
ness to disclose sexual practices to care providers [45].
They may also not consider themselves at risk of HIV
infection. This is the main reason why people do not test
for HIV, according to a recent systematic literature re-
view summarizing barriers to HIV testing in Europe
[21]. In addition, healthcare providers themselves may
be ill at ease when dealing with sexuality and behavior
risk assessment [46,47].
Even in patients identified as being at high risk of HIV
infection, our study illustrates the failure to propose an
HIV test: only one test proposed out of two MSM iden-
tified. Barriers to HIV testing on the part of the
healthcare provider include a lack of training in HIV
testing and a lack of self-confidence when proposing it
[21]. The consent process and counseling requirements
have been reported to be burdensome, particularly for
general practitioners [20].
Thus, these findings suggest that risk-factor-based
HIV testing is insufficient because its application is in-
sufficient. In this situation, routine HIV testing may be
attractive because it does not need risk assessment and
follows an opt-out process. However, in US as in France
where it is recommended, it is not widely applied be-
cause of implementation difficulties, and high costs
[30-32,48]. Haukoos et al. [49] have recently proposed a
score to identify people at risk of being HIV-infected
based on eight demographical and behavioral items. Al-
though this score require a minimum of risk assessment
and may need validation for French population, it is a
starting point to re-think routine HIV testing, and high-
light specific populations at risk for HIV to be tested
such as men. Routine screening can also be restricted to
high prevalence geographical areas.
In patients with STIs, a test was only proposed to one
out of two patients although a STI diagnosis is an indi-
cation for an HIV test [24,28]. In patients with other
HIV-related conditions who sought care, frequencies of
missed opportunities were even higher, as high as 98%
for those with recurrent bacterial infections. We found
that patients who did not receive a test proposal had
been diagnosed with significantly lower CD4 cell counts
than patients who were proposed a test. This confirms
that patients without a test proposal were probably HIV-
infected when they consulted and thus had had a loss of
chance of being diagnosed and entering into care. It is
crucial to bring to healthcare providers this kind of evi-
dence regarding HIV testing for them to improve their
knowledge about HIV-related conditions and thus to in-
crease the proportion of patients tested for HIV. An
European study has been currently conducted to assess
the prevalence of undiagnosed HIV infection in patients
with some particular HIV indicator diseases (e.g.
mononucleosis-like illness or malignant lymphoma); re-
sults show HIV prevalence above 1% in patients with
these HIV indicator diseases [50]. This is another argu-
ment to convince healthcare providers of the importance
of testing proposal for patients with HIV indicator
diseases.
Conclusions
This study illustrates that the rate of missed opportun-
ities for HIV testing remains unacceptable and highlights
the low efficiency of risk-factor- and symptom-based
HIV testing as it is currently applied. We must therefore
reinforce and implement new HIV screening strategies.
Testing initiated by the healthcare provider should be
promoted. Because risk-factor based testing is not suffi-
cient, routine screening should be considered in particu-
lar in high prevalence geographical areas and/or specific
populations. In our study, most persons had contact
with healthcare facilities and particularly general practi-
tioners who should play an important role in future HIV
testing strategies. But we must train physicians to better
recognize HIV-related conditions and develop tools such
as behavioral and clinical instruments to better identify
those at high risk of HIV infection in whom HIV testing
should be regularly performed. HIV testing has become
a major tool and the basis of the new prevention strat-
egies such as the Test and Treat strategy; it should be
promoted urgently.
Table 4 HIV test proposals according to possibly HIV-
related conditions
HIV-related condition N HIV test proposal n(%)
Recurrent bacterial infection 87 2 (2%)
Generalized lymphadenopathy 46 5 (11%)
Varicella zoster 35 5 (14%)
Unexplained weight loss ≥10% 45 7 (16%)
Diarrhea ≥1 month 36 6 (17%)
Fever ≥1 month 22 5 (23%)
Sexually transmitted infection 101 54 (53%)
Proportion of HIV test proposals upon first visit in patients who sought care
for possible HIV-related conditions during the 3-month to 3-year period prior
to HIV diagnosis. Main HIV-related conditions are given.
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